2005
DOI: 10.1007/s00280-004-0938-3
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: The unexpectedly high rate of cumulative toxicity observed in our study needs to be taken into consideration in future trials of CT-2103. Prior taxane use may not be a predictor of severe neurotoxicity.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
18
0

Year Published

2009
2009
2017
2017

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 29 publications
(18 citation statements)
references
References 10 publications
0
18
0
Order By: Relevance
“…Design and synthesis of PGG-PTX PGA-PTX (also known as CT-2103) was reported to produce complete regression of established tumors in mice 6 and has demonstrated activity in Phase I 19,20 and Phase II 21 clinical trials. However, the combination of CT-2103 and carboplatin was not superior to PTX and carboplatin in a randomized Phase III trial in patients with lung cancer.…”
Section: Resultsmentioning
confidence: 99%
“…Design and synthesis of PGG-PTX PGA-PTX (also known as CT-2103) was reported to produce complete regression of established tumors in mice 6 and has demonstrated activity in Phase I 19,20 and Phase II 21 clinical trials. However, the combination of CT-2103 and carboplatin was not superior to PTX and carboplatin in a randomized Phase III trial in patients with lung cancer.…”
Section: Resultsmentioning
confidence: 99%
“…Many clinical studies have been carried out on PDCs (e.g., OPAXIO) [26]. The main clinical outcomes have been summarized in extensive reviews [55][56][57], but, as yet, a detailed analysis of which tumour types are proving more responsive to this type of drug delivery technology is still missing.…”
Section: Resultsmentioning
confidence: 99%
“…The polymer carrier also permits incorporation of membrane active peptides or targeting agents into the conjugate structure, the latter designed to enhance receptor-mediated uptake into tumour cells or organs containing tumour metastases, and increase the exposure of the tumour to active drug while minimizing exposure of normal tissues (31). Thoughtful design of macromolecular drug conjugates should yield a range of new approaches to cancer treatment with potentially significant benefits, and several have already progressed as far as clinical evaluation in phase I studies (23,(31)(32)(33).…”
Section: Discussionmentioning
confidence: 99%